Table 1.
Summary of the PLA-derivative nanoparticles.
| Material | Processing Technique | Polymer Structure | Molecular Weight (kDa) | Material Characterisation 1 | Studies 2 | Ref. |
|---|---|---|---|---|---|---|
| Nanoparticles | Double emulsion-solvent evaporation | PLLA-PEG | 85–160 | Size, PDI, EE (%) | In vitro/in vivo | [149] |
| PLLA | ||||||
| Nanoprecipitation-solvent displacement | Rac-PLA | - | Size, PDI, Z-potential, LE (%), EE (%), Morphology (SEM) | In vitro/in vivo/clinical | [150] | |
| Interfacial deposition-solvent displacement | Rac-PLA-Peg | 18–28 | Size, PDI, Z-potential | In vivo | [151] | |
| Emulsion-solvent evaporation | Maleimide-PEG-PLA (no PLA specification) | PEG3-PLA70 | Size, Z-potential, Morphology (TEM) | In vivo | [152] | |
| Methoxy-PEG-PLA (no PLA specification) | PEG3-PLA50 | |||||
| Emulsion-solvent evaporation | PLGA (75L:25G) | 15 | CE (%) complexation efficiency, Z-potential, morphology (SEM) | In vivo | [153] | |
| Nanoprecipitation-solvent displacement | Trastuzumab-PEIcoating-Rac-PLA | 22 | LE (%), EE (%), Morphology (TEM) | In vitro | [154] | |
| Emulsion-solvent evaporation | Maleimide-PEG-PLA (no PLA specification) | PEG3.4–PLA34 | Size, PDI, Z-potential, Morphology (TEM) | In vitro/In vivo | [155] | |
| Methoxy-PEG-PLA (no PLA specification) | PEG3.4–PLA30 | |||||
| Emulsion-solvent evaporation | Maleimide-PEG-PLA (no PLA specification) | PEG3.4–PLA34 | Size, PDI, Z-potential, EE (%), LC (%), Morphology (TEM) | In vitro/In vivo | [156] | |
| Methoxy-PEG-PLA (no PLA specification) | PEG3.4–PLA30 | |||||
| Nanoprecipitation-solvent displacement | Rac-PLA-OH | 10.5 | Size, Z-potential, Morphology (TEM) | In vitro | [157] | |
| Rac-PLA-PEG-NH2 | PLA4.5–PEG3.5–NH2 | |||||
| Nanoprecipitation-solvent evaporation | PLA | - | Size, Z-potential, pH, EE (%), LE (%), Morphology (AFM, SEM), Molecular structure (FTIR) | In vitro | [159] |
1 After processing; 2 In vitro/in vivo/clinical.